Robert A. Beckman, Ph.D. - Publications

Affiliations: 
2005 University of California, Los Angeles, Los Angeles, CA 
Area:
Physical Chemistry, General Physics, Electronics and Electrical Engineering

4/117 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2006 Beckman R, Beverly K, Boukai A, Bunimovich Y, Choi JW, DeIonno E, Green J, Johnston-Halperin E, Luo Y, Sheriff B, Stoddart F, Heath JR. Spiers Memorial Lecture. Molecular mechanics and molecular electronics. Faraday Discussions. 131: 9-22; discussion 91-. PMID 16512361 DOI: 10.1039/B513148K  0.369
2005 Beckman R, Johnston-Halperin E, Luo Y, Green JE, Heath JR. Bridging dimensions: demultiplexing ultrahigh-density nanowire circuits. Science (New York, N.Y.). 310: 465-8. PMID 16195426 DOI: 10.1126/Science.1114757  0.661
2004 Beckman RA, Johnston-Halperin E, Melosh NA, Luo Y, Green JE, Heath JR. Fabrication of conducting Si nanowire arrays Journal of Applied Physics. 96: 5921-5923. DOI: 10.1063/1.1801155  0.623
2002 Diehl MR, Yaliraki SN, Beckman RA, Barahona M, Heath JR. Self-assembled, deterministic carbon nanotube wiring networks. Angewandte Chemie (International Ed. in English). 41: 353-6. PMID 12491431 DOI: 10.1002/1521-3773(20020118)41:2<353::AID-ANIE353>3.0.CO;2-Y  0.418
Low-probability matches (unlikely to be authored by this person)
1997 Reid PJ, Esposito AP, Foster CE, Beckman RA. Evidence for the 2B1-2A1 electronic transition in chlorine dioxide from resonance Raman depolarization ratios Journal of Chemical Physics. 107: 8262-8274. DOI: 10.1063/1.475028  0.243
1997 Esposito AP, Foster CE, Beckman RA, Reid PJ. Excited-state dynamics of chlorine dioxide in the condensed phase from resonance Raman intensities Journal of Physical Chemistry A. 101: 5309-5319. DOI: 10.1021/Jp9637035  0.241
1995 Qi PX, Fuentes EJ, Beckman RA, Di Stefano DL, Joshua Wand A. Solution structures of horse ferro- and ferricytochrome c using 2D and 3D 1H NMR and restrained simulated annealing Techniques in Protein Chemistry. 6: 511-519. DOI: 10.1016/S1080-8914(06)80062-1  0.163
2012 Beckman RA, Schemmann GS, Yeang C. Abstract LB-448: Next generation personalized medicine strategies incorporating genetic dynamics and single cell heterogeneity may lead to improved outcomes Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-448  0.147
1996 Qi PX, Beckman RA, Wand AJ. Solution structure of horse heart ferricytochrome c and detection of redox-related structural changes by high-resolution 1H NMR. Biochemistry. 35: 12275-86. PMID 8823161 DOI: 10.1021/BI961042W  0.133
2012 Beckman RA, Schemmann GS, Yeang CH. Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer. Proceedings of the National Academy of Sciences of the United States of America. 109: 14586-91. PMID 22891318 DOI: 10.1073/Pnas.1203559109  0.122
2014 Orcutt KD, Adams GP, Wu AM, Silva M, Hoppin J, Harwell C, Matsumura M, Kotsuma M, Freeman D, Tse A, Greenberg J, Scott A, Beckman RA. Abstract 4300: Receptor occupancy and tumor penetration by antibodies, peptides, and antibody fragments: Molecular simulation of imaging assessment Cancer Research. 74: 4300-4300. DOI: 10.1158/1538-7445.Am2014-4300  0.104
1994 Beckman RA, Litwin S, Wand AJ. Statistical strategy for stereospecific hydrogen NMR assignments: validation procedures for the floating prochirality method. Journal of Biomolecular Nmr. 3: 675-700. PMID 8111232 DOI: 10.1007/BF00198371  0.102
2014 Beckman RA, Yeang CH. Nonstandard personalized medicine strategies for cancer may lead to improved patient outcomes Personalized Medicine. 11: 705-719. DOI: 10.2217/pme.14.57  0.102
2014 Beckman RA, Yeang CH. Nonstandard personalized medicine strategies for cancer may lead to improved patient outcomes. Personalized Medicine. 11: 705-719. PMID 29764056 DOI: 10.2217/pme.14.57  0.101
2020 Boca S, Bhuvaneshwar K, Fernandez-Vega V, Kancherla J, Rao S, Madhavan S, Riggins R, Beckman RA, Corrada Bravo H, Scampavia L, Spicer T. Prioritizing targeted therapies in an evidence-based manner, integrating biological context and functional precision medicine. Journal of Clinical Oncology. 38: e14065-e14065. DOI: 10.1200/Jco.2020.38.15_Suppl.E14065  0.1
2016 Yeang CH, Beckman RA. Long range personalized cancer treatment strategies incorporating evolutionary dynamics. Biology Direct. 11: 56. PMID 27770811 DOI: 10.1186/s13062-016-0153-2  0.099
2007 Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer. 109: 170-9. PMID 17154393 DOI: 10.1002/Cncr.22402  0.098
2016 Cunningham JM, Prins P, Conkright B, Boca S, Rao S, Gabrielson A, Oseran A, Beckman R, Al-hajeili M, Madhaven S, Marshall J. Molecular profiling of TOPO1: A way to evaluate irinotecan treatment in colorectal cancer? Journal of Clinical Oncology. 34: 546-546. DOI: 10.1200/JCO.2016.34.4_SUPPL.546  0.096
2017 Orcutt KD, Adams GP, Wu AM, Silva MD, Harwell C, Hoppin J, Matsumura M, Kotsuma M, Greenberg J, Scott AM, Beckman RA. Molecular Simulation of Receptor Occupancy and Tumor Penetration of an Antibody and Smaller Scaffolds: Application to Molecular Imaging. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 28213834 DOI: 10.1007/S11307-016-1041-Y  0.093
2006 Beckman RA, Moreland D, Louise-May S, Humblet C. RNA unrestrained molecular dynamics ensemble improves agreement with experimental NMR data compared to single static structure: a test case. Journal of Computer-Aided Molecular Design. 20: 263-79. PMID 17006738 DOI: 10.1007/s10822-006-9049-z  0.09
2016 Trusheim M, Ackerman Shrier A, Antonijevic Z, Beckman RA, Campbell RK, Chen C, Flaherty K, Loewy J, Lacombe D, Madhavan S, Selker H, Esserman L. PIPELINEs: Creating comparable clinical knowledge efficiently by linking trial platforms. Clinical Pharmacology and Therapeutics. PMID 27643536 DOI: 10.1002/cpt.514  0.086
2005 Yan L, Beckman RA. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. Biotechniques. 39: 565-8. PMID 16235569  0.086
2009 Yan L, Beckman R. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. Biotechniques. 39: S565-8. PMID 18957038 DOI: 10.2144/000112043  0.086
1994 Beckman RA, Loeb LA. Multi-stage proofreading in DNA replication. Quarterly Reviews of Biophysics. 26: 225-331. PMID 8022969 DOI: 10.1017/S0033583500002869  0.084
1995 Beckman RA, Zuiderweg ERP. Guidelines for the Use of Oversampling in Protein NMR Journal of Magnetic Resonance, Series A. 113: 223-231. DOI: 10.1006/jmra.1995.1083  0.083
2019 Akhmetzhanov AR, Kim JW, Sullivan R, Beckman RA, Tamayo P, Yeang CH. Modelling bistable tumour population dynamics to design effective treatment strategies. Journal of Theoretical Biology. PMID 31077681 DOI: 10.1016/j.jtbi.2019.05.005  0.082
2008 Yan L, Hsu K, Beckman RA. Antibody-based therapy for solid tumors. Cancer Journal (Sudbury, Mass.). 14: 178-83. PMID 18536557 DOI: 10.1097/PPO.0b013e318172d71a  0.079
2020 Beckman RA, Kareva I, Adler FR. How Should Cancer Models Be Constructed? Cancer Control : Journal of the Moffitt Cancer Center. 27: 1073274820962008. PMID 32991214 DOI: 10.1177/1073274820962008  0.074
2008 Bodmer W, Bielas JH, Beckman RA. Genetic instability is not a requirement for tumor development. Cancer Research. 68: 3558-60; discussion . PMID 18483234 DOI: 10.1158/0008-5472.Can-07-6544  0.072
2020 Kancherla J, Rao S, Bhuvaneshwar K, Riggins RB, Beckman RA, Madhavan S, Corrada Bravo H, Boca SM. Evidence-Based Network Approach to Recommending Targeted Cancer Therapies. Jco Clinical Cancer Informatics. 4: 71-88. PMID 31990579 DOI: 10.1200/CCI.19.00097  0.072
2011 Beckman RA, von Roemeling R, Scott AM. Monoclonal antibody dose determination and biodistribution into solid tumors. Therapeutic Delivery. 2: 333-44. PMID 22834004  0.071
2012 Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, ... ... Beckman R, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2307-13. PMID 22547604 DOI: 10.1200/Jco.2011.39.1540  0.071
2014 Chen C, Beckman RA. Maximizing return on socioeconomic investment in phase II proof-of-concept trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1730-4. PMID 24526732 DOI: 10.1158/1078-0432.CCR-13-2312  0.071
2017 Li W, Chen C, Li X, Beckman RA. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines. Statistics in Medicine. PMID 28303586 DOI: 10.1002/sim.7272  0.07
2010 Scott A, Lee F, Cartwright G, O'Keefe G, Beckman R, Fujiwara K, von Roemeling R. 240 Molecular imaging of Death Receptor 5 (DR5) occupancy in-vivo by humanized monoclonal antibody CS-1008 European Journal of Cancer Supplements. 8: 78. DOI: 10.1016/S1359-6349(10)71945-5  0.07
2016 Rao S, Beckman RA, Riazi S, Yabar CS, Boca SM, Marshall JL, Pishvaian MJ, Brody JR, Madhavan S. Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. Oncotarget. PMID 27888622 DOI: 10.18632/Oncotarget.13544  0.07
2022 Sharma V, Fong A, Beckman RA, Rao S, Boca SM, McGarvey PB, Ratwani RM, Madhavan S. Eye-Tracking Study to Enhance Usability of Molecular Diagnostics Reports in Cancer Precision Medicine. Jco Precision Oncology. 2: 1-11. PMID 35135129 DOI: 10.1200/PO.17.00296  0.068
2013 LoRusso P, Jänne PA, Oliveira M, Rizvi N, Malburg L, Keedy V, Yee L, Copigneaux C, Hettmann T, Wu CY, Ang A, Halim AB, Beckman RA, Beaupre D, Berlin J. Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3078-87. PMID 23591447 DOI: 10.1158/1078-0432.CCR-12-3051  0.066
2013 Burvenich IJ, Lee FT, Cartwright GA, O'Keefe GJ, Makris D, Cao D, Gong S, Chueh AC, Mariadason JM, Brechbiel MW, Beckman RA, Fujiwara K, von Roemeling R, Scott AM. Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5984-93. PMID 24045184 DOI: 10.1158/1078-0432.Ccr-12-3104  0.065
2011 Beckman RA, Clark J, Chen C. Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nature Reviews. Drug Discovery. 10: 735-48. PMID 21959287 DOI: 10.1158/AACR.EDB-14-8039  0.064
2001 Clarke-Pearson DL, Van Le L, Iveson T, Whitney CW, Hanjani P, Kristensen G, Malfetano JH, Beckman RA, Ross GA, Lane SR, DeWitte MH, Fields SZ. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 3967-75. PMID 11579118 DOI: 10.1200/JCO.2001.19.19.3967  0.064
2005 Beckman RA, Loeb LA. Genetic instability in cancer: Theory and experiment Seminars in Cancer Biology. 15: 423-435. PMID 16043359 DOI: 10.1016/J.Semcancer.2005.06.007  0.064
2017 Ondra T, Jobjörnsson S, Beckman RA, Burman CF, König F, Stallard N, Posch M. Optimized adaptive enrichment designs. Statistical Methods in Medical Research. 962280217747312. PMID 29254436 DOI: 10.1177/0962280217747312  0.063
2018 Mabrey FL, Chien SS, Martins TS, Annis J, Sekizaki TS, Dai J, Beckman RA, Loeb LA, Carson A, Patay B, Blau CA, Oehler VG, Celik SS, Lee S, Monnat RJ, et al. High Throughput Drug Screening of Leukemia Stem Cells Reveals Resistance to Standard Therapies and Sensitivity to Other Agents in Acute Myeloid Leukemia Blood. 132: 180-180. DOI: 10.1182/Blood-2018-180  0.062
2020 He L, Du L, Antonijevic Z, Posch M, Korostyshevskiy VR, Beckman RA. Efficient two-stage sequential arrays of proof of concept studies for pharmaceutical portfolios. Statistical Methods in Medical Research. 962280220958177. PMID 32955400 DOI: 10.1177/0962280220958177  0.061
2020 Ghadessi M, Tang R, Zhou J, Liu R, Wang C, Toyoizumi K, Mei C, Zhang L, Deng CQ, Beckman RA. A roadmap to using historical controls in clinical trials - by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG). Orphanet Journal of Rare Diseases. 15: 69. PMID 32164754 DOI: 10.1186/s13023-020-1332-x  0.061
2007 Nemeth JA, Nakada MT, Trikha M, Lang Z, Gordon MS, Jayson GC, Corringham R, Prabhakar U, Davis HM, Beckman RA. Alpha-v integrins as therapeutic targets in oncology. Cancer Investigation. 25: 632-46. PMID 18027153 DOI: 10.1080/07357900701522638  0.06
2013 Forero-Torres A, Infante JR, Waterhouse D, Wong L, Vickers S, Arrowsmith E, He AR, Hart L, Trent D, Wade J, Jin X, Wang Q, Austin T, Rosen M, Beckman R, et al. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer. Cancer Medicine. 2: 925-32. PMID 24403266 DOI: 10.1002/cam4.137  0.059
2022 Gould AL, Campbell RK, Loewy JW, Beckman RA, Dey J, Schiel A, Burman CF, Zhou J, Antonijevic Z, Miller ER, Tang R. A framework for assessing the impact of accelerated approval. Plos One. 17: e0265712. PMID 35749431 DOI: 10.1371/journal.pone.0265712  0.059
2015 Mendell J, Freeman DJ, Feng W, Hettmann T, Schneider M, Blum S, Ruhe J, Bange J, Nakamaru K, Chen S, Tsuchihashi Z, von Pawel J, Copigneaux C, Beckman RA. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer. Ebiomedicine. 2: 264-71. PMID 26137564 DOI: 10.1016/j.ebiom.2015.02.005  0.058
2002 Gore M, Oza A, Rustin G, Malfetano J, Calvert H, Clarke-Pearson D, Carmichael J, Ross G, Beckman RA, Fields SZ. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. European Journal of Cancer (Oxford, England : 1990). 38: 57-63. PMID 11750840 DOI: 10.1016/S0959-8049(01)00188-5  0.058
2016 Chen C, Li X(, Yuan S, Antonijevic Z, Kalamegham R, Beckman RA. Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One Study Statistics in Biopharmaceutical Research. 8: 248-257. DOI: 10.1080/19466315.2016.1193044  0.056
2020 Aranha MP, Jewel YSM, Beckman RA, Weiner LM, Mitchell JC, Parks JM, Smith JC. Combining Three-Dimensional Modeling with Artificial Intelligence to Increase Specificity and Precision in Peptide-MHC Binding Predictions. Journal of Immunology (Baltimore, Md. : 1950). PMID 32878910 DOI: 10.4049/Jimmunol.1900918  0.056
1986 Kunkel TA, Beckman RA, Loeb LA. On the fidelity of DNA synthesis. Pyrophosphate-induced misincorporation allows detection of two proofreading mechanisms. Journal of Biological Chemistry. 261: 13610-13616. DOI: 10.1016/S0021-9258(18)67064-4  0.054
2011 Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodríguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodon J, Di Cosimo S, Brown H, Clark J, Hardwick JS, Beckman RA, et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6304-12. PMID 21810918 DOI: 10.1158/1078-0432.CCR-10-3336  0.054
2019 Li W, Zhao J, Li X, Chen C, Beckman RA. Multi-stage enrichment and basket trial designs with population selection. Statistics in Medicine. PMID 31621949 DOI: 10.1002/sim.8371  0.052
2012 Beckman R, Schemmann G, Yeang C. 265 Next Generation Personalized Medicine Strategies Incorporating Genetic Dynamics and Single Cell Heterogeneity May Lead to Improved Outcomes European Journal of Cancer. 48: 81-82. DOI: 10.1016/S0959-8049(12)72063-4  0.052
2015 Ciprotti M, Tebbutt NC, Lee FT, Lee ST, Gan HK, McKee DC, O'Keefe GJ, Gong SJ, Chong G, Hopkins W, Chappell B, Scott FE, Brechbiel MW, Tse AN, Jansen M, ... ... Beckman RA, et al. Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26124477 DOI: 10.1200/JCO.2014.60.4256  0.05
2007 Mullamitha SA, Ton NC, Parker GJ, Jackson A, Julyan PJ, Roberts C, Buonaccorsi GA, Watson Y, Davies K, Cheung S, Hope L, Valle JW, Radford JA, Lawrance J, Saunders MP, ... ... Beckman RA, et al. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2128-35. PMID 17404096 DOI: 10.1158/1078-0432.CCR-06-2779  0.05
2013 Ciprotti M, Tebbutt NC, Lee FT, Lee ST, McKee DC, O'Keefe GJ, Gong SJ, Chong G, Gan HK, Hopkins W, Chappell B, Scott FE, Brechbiel MW, Tse AN, Jansen M, ... ... Beckman RA, et al. A phase I imaging and pharmacodynamic trial of CS-1008 in patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 31: 2583-2583. DOI: 10.1200/jco.2013.31.15_suppl.2583  0.05
2013 Reck M, Krzakowski M, Chmielowska E, Sebastian M, Hadler D, Fox T, Wang Q, Greenberg J, Beckman RA, von Pawel J. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 82: 441-8. PMID 24148258 DOI: 10.1016/j.lungcan.2013.09.014  0.049
2014 Yap TA, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, Papadopoulos KP, Olmos D, Baird R, Delgado L, Tetteh E, Beckman RA, Lupinacci L, Riisnaes R, Decordova S, et al. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5672-85. PMID 25239610 DOI: 10.1158/1078-0432.CCR-14-0868  0.048
2013 Beckman RA, Chen C. New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programs. Chinese Journal of Cancer. 32: 233-41. PMID 23489587 DOI: 10.5732/cjc.012.10248  0.048
2017 Beckman RA, Loeb LA. Evolutionary dynamics and significance of multiple subclonal mutations in cancer. Dna Repair. PMID 28652129 DOI: 10.1016/J.Dnarep.2017.06.002  0.048
2012 Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, Deeken JF, He AR, Daniel H, Halim AB, Zahir H, Copigneaux C, Liu K, Beckman RA, Demetri GD. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer. 118: 5403-13. PMID 22570147 DOI: 10.1002/cncr.27526  0.047
2006 O??Day S, Richards J, Corringham R, Beckman R, Lang Z, Pavlick A. CNTO 95, a fully human monoclonal antibody to alpha-v integrins: results of a phase I/II study in patients with metastatic melanoma Melanoma Research. 16: S39-S40. DOI: 10.1097/00008390-200609001-00069  0.047
2006 O' Day S, Richards J, Jiao T, Mata M, Prabhakar U, Beckman R, Lang Z, Pavlick A. 218 POSTER Phase I/II study of CNTO 95, a fully human monoclonal antibody (mAb) to alpha-v integrins, in patients with metastatic melanoma European Journal of Cancer Supplements. 4: 68. DOI: 10.1016/S1359-6349(06)70223-3  0.046
2015 Papadopoulos KP, Moore KN, Lush R, Desai M, Mahmood S, Beckman RA, Mendell-Harary J. Pharmacokinetics, safety, and tolerability of a new patritumab formulation in patients with advanced, refractory solid tumors. Journal of Clinical Oncology. 33: e14026-e14026. DOI: 10.1200/JCO.2015.33.15_SUPPL.E14026  0.046
2005 Jayson GC, Mullamitha S, Ton C, Valle J, Jackson A, Julyan P, Munteanu MC, Davis HM, Lang Z, Beckman RA. Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to αv integrins, in patients with solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3113. PMID 27946099 DOI: 10.1200/jco.2005.23.16_suppl.3113  0.046
2015 Cheng AL, Kang YK, He AR, Lim HY, Ryoo BY, Hung CH, Sheen IS, Izumi N, Austin T, Wang Q, Greenberg J, Shiratori S, Beckman RA, Kudo M. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: a phase 2 randomized study. Journal of Hepatology. PMID 26071796 DOI: 10.1016/j.jhep.2015.06.001  0.046
2010 Fox EJ, Beckman RA, Loeb LA. Reply: Is There Any Genetic Instability in Human Cancer? Dna Repair. 9: 859-860. PMID 20703319 DOI: 10.1016/J.Dnarep.2010.05.006  0.045
2007 Chu FM, Picus J, Mata M, Kopacynski C, Foster B, Lang Z, Beckman RA, Dreicer R. Phase I study of CNTO 95, a fully human monoclonal antibody to αv integrins, docetaxel, and prednisone in hormone refractory prostate cancer patients (HRPCP) Journal of Clinical Oncology. 25: 15595-15595. DOI: 10.1200/JCO.2007.25.18_SUPPL.15595  0.044
2000 Eckardt J, Fanucchi M, Stewart D, Beckman R, Dobbs T, Wilson J, Ho M, Fields S. A phase I/II study using oral topotecan (OT) with intravenous paclitaxel (P) as first-line therapy for patients (pts) with advanced non-small cell lung cancer (NSCLC) Lung Cancer. 29: 7. DOI: 10.1016/S0169-5002(00)80017-3  0.044
2015 Beckman RA, Chen C. Translating predictive biomarkers within oncology clinical development programs. Biomarkers in Medicine. 9: 851-62. PMID 26330133 DOI: 10.2217/bmm.15.56  0.044
2009 Chen C, Beckman RA. Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions. Journal of Biopharmaceutical Statistics. 19: 424-36. PMID 19384686 DOI: 10.1080/10543400902800478  0.043
2022 He L, Ren Y, Chen H, Guinn D, Parashar D, Chen C, Yuan SS, Korostyshevskiy V, Beckman RA. Efficiency of a randomized confirmatory basket trial design constrained to control the family wise error rate by indication. Statistical Methods in Medical Research. 9622802221091901. PMID 35404188 DOI: 10.1177/09622802221091901  0.043
2019 Beckman RA, Kohrn B, Loubet-Senear K, Dunn J, OSullivan J, Bronner M, Loeb LA. Abstract 3770: Unexpectedly high subclonal mutational diversity in human colorectal cancer and its significance Cancer Research. 79: 3770-3770. DOI: 10.1158/1538-7445.Sabcs18-3770  0.042
2016 Ondra T, Jobjörnsson S, Beckman RA, Burman CF, König F, Stallard N, Posch M. Optimizing Trial Designs for Targeted Therapies. Plos One. 11: e0163726. PMID 27684573 DOI: 10.1371/journal.pone.0163726  0.042
2012 Cheng A, Kang Y, Ryoo B, Yen C, Lim HY, Oh D, Austin T, Wang Q, Greenberg J, Beckman RA, Kudo M. Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 30: e14617-e14617. DOI: 10.1200/jco.2012.30.15_suppl.e14617  0.042
2022 Tang RS, Zhu J, Chen TT, Liu F, Jiang X, Huang B, Lee JJ, Beckman RA. Impact of COVID-19 pandemic on oncology clinical trial design, data collection and analysis. Contemporary Clinical Trials. 116: 106736. PMID 35331946 DOI: 10.1016/j.cct.2022.106736  0.041
2000 Akhtar S, Beckman RA, Mould DR, Doyle E, Fields SZ, Wright J. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan Cancer Chemotherapy and Pharmacology. 46: 204-210. PMID 11021737 DOI: 10.1007/s002800000141  0.041
2016 Yuan SS, Chen A, He L, Chen C, Gause CK, Beckman RA. On Group Sequential Enrichment Design for Basket Trial Statistics in Biopharmaceutical Research. 8: 293-306. DOI: 10.1080/19466315.2016.1200999  0.041
2022 Madhavan S, Beckman RA, McCoy MD, Pishvaian MJ, Brody JR, Macklin P. Envisioning the future of precision oncology trials. Nature Cancer. 2: 9-11. PMID 35121893 DOI: 10.1038/s43018-020-00163-8  0.041
2021 Madhavan S, Beckman RA, McCoy MD, Pishvaian MJ, Brody JR, Macklin P. Envisioning the future of precision oncology trials Nature Cancer. 2: 9-11. DOI: 10.1038/s43018-020-00163-8  0.041
2018 Chen C, Li XN, Li W, Beckman RA. Adaptive expansion of biomarker populations in phase 3 clinical trials. Contemporary Clinical Trials. 71: 181-185. PMID 29981858 DOI: 10.1016/j.cct.2018.07.001  0.039
2016 Fox EJP, Schmitt MW, Reid-Bayliss KS, Beckman RA, Loeb LA. Abstract LB-338: Extensive subclonal mutations in human colorectal cancers detected by duplex sequencing Cancer Research. 76: 3377-3377. DOI: 10.1158/1538-7445.Am2016-Lb-338  0.037
2019 Loeb LA, Kohrn BF, Loubet-Senear KJ, Dunn YJ, Ahn EH, O'Sullivan JN, Salk JJ, Bronner MP, Beckman RA. Extensive subclonal mutational diversity in human colorectal cancer and its significance. Proceedings of the National Academy of Sciences of the United States of America. PMID 31806761 DOI: 10.1073/Pnas.1910301116  0.037
1988 Beckman RA, McFall PJ, Sikic BI, Smith SD. Doxorubicin and the alkylating anthracycline 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin: Comparative in vitro potency against leukemia and bone marrow cells Journal of the National Cancer Institute. 80: 361-365. PMID 3357201 DOI: 10.1093/Jnci/80.5.361  0.035
2008 Loeb LA, Bielas JH, Beckman RA. Cancers exhibit a mutator phenotype: Clinical implications Cancer Research. 68: 3551-3557. PMID 18483233 DOI: 10.1158/0008-5472.Can-07-5835  0.033
1985 Beckman RA, Mildvan AS, Loeb LA. On the fidelity of DNA replication: manganese mutagenesis in vitro. Biochemistry. 24: 5810-7. PMID 3910084 DOI: 10.1021/Bi00342A019  0.033
2009 Yan L, Ehrlich PJ, Gibson R, Pickett C, Beckman RA. How can we improve antibody-based cancer therapy? Mabs. 1: 67-70. PMID 20046576  0.032
2020 Beckman RA, Loeb LA. Rare Mutations in Cancer Drug Resistance and Implications for Therapy. Clinical Pharmacology and Therapeutics. PMID 32648584 DOI: 10.1002/Cpt.1938  0.032
2001 Gore M, Rustin G, Schüller J, Lane SR, Hearn S, Beckman RA, Ross G. Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer. British Journal of Cancer. 84: 1043-6. PMID 11308251 DOI: 10.1054/bjoc.2001.1726  0.032
2014 Mendell-Harary J, Ruhe J, Schneider M, Feng W, Freeman DJ, Nakamaru K, Jin X, Tsuchihashi Z, Von Pawel J, Copigneaux C, Beckman RA. Identification of a predictive biomarker for patritumab (P), an anti-HER3 monoclonal antibody, in advanced NSCLC. Journal of Clinical Oncology. 32: e19016-e19016. DOI: 10.1200/JCO.2014.32.15_SUPPL.E19016  0.03
2017 Chen C, Deng Q, He L, Mehrotra D, Rubin EH, Beckman RA. How many tumor indications should be initially screened in development of next generation immunotherapies? Contemporary Clinical Trials. PMID 28341249 DOI: 10.1016/j.cct.2017.03.012  0.029
2009 Chen C, Beckman RA. Hypothesis Testing in a Confirmatory Phase III Trial With a Possible Subset Effect Statistics in Biopharmaceutical Research. 1: 431-440. DOI: 10.1198/sbr.2009.0039  0.029
2015 Pawel Jv, Tseng J, Dediu M, Schumann C, Moritz B, Mendell J, Jin X, Feng W, Copigneaux C, Beckman R. Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs) Pneumologie. 69. DOI: 10.1055/S-0035-1544763  0.028
2014 Von Pawel J, Tseng J, Dediu M, Schumann C, Moritz B, Mendell-Harary J, Jin X, Feng W, Copigneaux C, Beckman RA. Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs). Journal of Clinical Oncology. 32: 8045-8045. DOI: 10.1200/JCO.2014.32.15_SUPPL.8045  0.028
1992 Görlach M, Wittekind M, Beckman RA, Mueller L, Dreyfuss G. Interaction of the RNA-binding domain of the hnRNP C proteins with RNA. The Embo Journal. 11: 3289-95. PMID 1380452 DOI: 10.1002/J.1460-2075.1992.Tb05407.X  0.027
2016 Chen C, Li N, Shentu Y, Pang L, Beckman RA. Adaptive Informational Design of Confirmatory Phase III Trials With an Uncertain Biomarker Effect to Improve the Probability of Success Statistics in Biopharmaceutical Research. 8: 237-247. DOI: 10.1080/19466315.2016.1173582  0.027
2010 Beckman RA. Efficiency of carcinogenesis: is the mutator phenotype inevitable? Seminars in Cancer Biology. 20: 340-52. PMID 20934514 DOI: 10.1016/j.semcancer.2010.10.004  0.027
2017 Kristof J, Sakrison K, Jin X, Nakamaru K, Schneider M, Beckman RA, Freeman D, Spittle C, Feng W. Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue. Biomarker Insights. 12: 1177271917699850. PMID 28469400 DOI: 10.1177/1177271917699850  0.027
2005 Beckman RA, Loeb LA. Negative clonal selection in tumor evolution Genetics. 171: 2123-2131. PMID 16143627 DOI: 10.1534/Genetics.105.040840  0.026
2018 Dillon MT, Grove L, Newbold KL, Shaw H, Brown NF, Mendell J, Chen S, Beckman RA, Jennings A, Ricamara M, Greenberg J, Forster M, Harrington KJ. Patritumab with Cetuximab Plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase-Ib Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30327312 DOI: 10.1158/1078-0432.CCR-18-1539  0.024
1999 Mobus V, Lane S, Fields S, Beckman R, Ross G, King K, Kettels J. Topotecan: tolerability, response rate and survival associated with extended therapy in relapsed ovarian cancer — Results of a pooled analysis of 523 patients European Journal of Cancer. 35: S232. DOI: 10.1016/S0959-8049(99)81329-X  0.021
2022 Roszik J, Lee JJ, Wu YH, Liu X, Kawakami M, Kurie JM, Belouali A, Boca SM, Gupta S, Beckman RA, Madhavan S, Dmitrovsky E. Real-World Studies Link Nonsteroidal Anti-inflammatory Drug Use to Improved Overall Lung Cancer Survival. Cancer Research Communications. 2: 590-601. PMID 35832288 DOI: 10.1158/2767-9764.crc-22-0179  0.02
2022 Beckman RA, Natanegara F, Singh P, Cooner F, Antonijevic Z, Liu Y, Mayer C, Price K, Tang R, Xia A, Apostolaros M, Granville C, Michaels D. Advancing innovative clinical trials to efficiently deliver medicines to patients. Nature Reviews. Drug Discovery. PMID 35760887 DOI: 10.1038/d41573-022-00109-y  0.019
2018 Guinn D, Ren Y, Wilhelm E, Deeb H, Brooks I, Korostyshevskiy V, Madhavan S, Beckman R. Utilizing Real-World Data to Inform a Confirmatory Basket Trial Design: Studying Use of Rituximab in Autoimmune Diseases Value in Health. 21: S229-S230. DOI: 10.1016/J.JVAL.2018.04.1555  0.018
2015 Beckman RA, Chen C. Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development. Advances in Experimental Medicine and Biology. 867: 81-90. PMID 26530361 DOI: 10.1007/978-94-017-7215-0_6  0.018
2006 Beckman RA, Loeb LA. Efficiency of carcinogenesis with and without a mutator mutation Proceedings of the National Academy of Sciences of the United States of America. 103: 14140-14145. PMID 16966602 DOI: 10.1073/Pnas.0606271103  0.017
1979 Loeb LA, Weymouth LA, Kunkel TA, Gopinathan KP, Beckman RA, Dube DK. On the fidelity of DNA replication. Cold Spring Harbor Symposia On Quantitative Biology. 43: 921-7. PMID 90579 DOI: 10.1101/Sqb.1979.043.01.101  0.011
2017 Shentu Y, Chen C, Pang L, Beckman RA. Auto-adaptive Alpha Allocation: A Strategy to Mitigate Risk on Study Assumptions Statistics in Biosciences. 10: 342-356. DOI: 10.1007/S12561-017-9192-1  0.01
2009 Beckman RA. Mutator mutations enhance tumorigenic efficiency across fitness landscapes. Plos One. 4: e5860. PMID 19517009 DOI: 10.1371/journal.pone.0005860  0.01
2009 Chen C, Beckman RA. Optimal Cost-Effective Go-No Go Decisions in Late-Stage Oncology Drug Development Statistics in Biopharmaceutical Research. 1: 159-169. DOI: 10.1198/sbr.2009.0027  0.01
2000 Beckman RA, Siden R, Yanik GA, Levine JE. Continuous octreotide infusion for the treatment of secretory diarrhea caused by acute intestinal graft-versus-host disease in a child Journal of Pediatric Hematology/Oncology. 22: 344-350. PMID 10959906 DOI: 10.1097/00043426-200007000-00013  0.01
1981 Loeb L, Dube D, Beckman R, Koplitz M, Gopinathan K. On the fidelity of DNA replication. Nucleoside monophosphate generation during polymerization. Journal of Biological Chemistry. 256: 3978-3987. DOI: 10.1016/s0021-9258(19)69555-4  0.01
1981 Kunkel T, Schaaper R, Beckman R, Loeb L. On the fidelity of DNA replication. Effect of the next nucleotide on proofreading. Journal of Biological Chemistry. 256: 9883-9889. DOI: 10.1016/s0021-9258(19)68712-0  0.01
Hide low-probability matches.